Cancer Genomics Laboratory

Group leader: Per Guldberg

Our group is interested in understanding the genomic alterations that drive cancer development, with a focus on DNA testing for early and non-invasive detection of cancer.

We are involved in the development and use of technologies for high-sensitivity detection of mutations, DNA methylation and other genomic alterations that can be used as specific biomarkers for cancer. Recent work includes the development of urine-based tests for detection of bladder cancer and other genitourinary cancers.

Per Guldberg

Per Guldberg

After obtaining a MS in Molecular Biology from the University of Copenhagen, I moved to the John F. Kennedy Institute, where my thesis involved the molecular characterization of phenylketonuria and other inherited genetic disorders.

In 1994, I started as a postdoc at the Danish Cancer Society, where I got interested in somatic genetic and epigenetic alterations in cancer as well as technologies for detecting these alterations. I have been a Group Leader since 2002.

Group members

Postdoc Christina Dahl
PhD student Louise Katrine Larsen

Five selected publications:

Christensen C, Bartkova J, Mistrik M, Hall A, Krarup Lange M, Ralfkiær U, Bartek J, Guldberg P. A short acidic motif in ARF guards against mitochondrial dysfunction and melanoma susceptibility. Nat.Commun. 2014; 5:5348 (PMID: 25370744)

Dahl C, Abildgaard C, Riber-Hansen R, Steiniche T, Lade-Keller J, Guldberg P. KIT is a frequent target for epigenetic silencing in cutaneous melanoma. J.Invest.Dermatol. 2015; 135:516-24 (PMID: 25178104)

Dahmcke CM, Steven KE, Larsen LK, Poulsen AL, Abdul-Al A, Dahl C, Guldberg P. A prospective blinded evaluation of urine-DNA testing for detection of urothelial bladder carcinoma in patients with gross hematuria. Eur.Urol. 2016;70:916-919 (PMID: 27417036)

Abildgaard C, Dahl C, Abdul-Al A, Christensen A, Guldberg P. Inhibition of retinoic acid receptor ß signaling confers glycolytic dependence and sensitization to dichloroacetate in melanoma cells. Oncotarget 2017;8:84210-84223 (PMID: 29137417)

Kirkin AF, Dzhandzhugazyan KN, Guldberg P, Fang JJ, Andersen RS, Dahl C, Mortensen J, Lundby T, Wagner A, Law I, Broholm H, Madsen L, Lundell-Ek C, Gjerstorff MF, Ditzel HJ, Jensen MR, Fischer W. Adoptive cancer immunotherapy using DNA-demethylated T helper cells as antigen-presenting cells. Nat.Commun. 2018;9:785 (PMID: 29511178)

ORCID:

Per Guldberg

0000-0002-4424-4803